» Articles » PMID: 34966273

Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats

Abstract

Recently, the stable gastric pentadecapeptide BPC 157 was shown to counteract major vessel occlusion syndromes, i.e., peripheral and/or central occlusion, while activating particular collateral pathways. We induced abdominal compartment syndrome (intra-abdominal pressure in thiopental-anesthetized rats at 25 mmHg (60 min), 30 mmHg (30 min), 40 mmHg (30 min), and 50 mmHg (15 min) and in esketamine-anesthetized rats (25 mmHg for 120 min)) as a model of multiple occlusion syndrome. By improving the function of the venous system with BPC 157, we reversed the chain of harmful events. Rats with intra-abdominal hypertension (grade III, grade IV) received BPC 157 (10 µg or 10 ng/kg sc) or saline (5 ml) after 10 min. BPC 157 administration recovered the azygos vein via the inferior-superior caval vein rescue pathway. Additionally, intracranial (superior sagittal sinus), portal, and caval hypertension and aortal hypotension were reduced, as were the grossly congested stomach and major hemorrhagic lesions, brain swelling, venous and arterial thrombosis, congested inferior caval and superior mesenteric veins, and collapsed azygos vein; thus, the failed collateral pathway was fully recovered. Severe ECG disturbances (i.e., severe bradycardia and ST-elevation until asystole) were also reversed. Microscopically, transmural hyperemia of the gastrointestinal tract, intestinal mucosa villi reduction, crypt reduction with focal denudation of superficial epithelia, and large bowel dilatation were all inhibited. In the liver, BPC 157 reduced congestion and severe sinusoid enlargement. In the lung, a normal presentation was observed, with no alveolar membrane focal thickening and no lung congestion or edema, and severe intra-alveolar hemorrhage was absent. Moreover, severe heart congestion, subendocardial infarction, renal hemorrhage, brain edema, hemorrhage, and neural damage were prevented. In conclusion, BPC 157 cured primary abdominal compartment syndrome.

Citing Articles

Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury.

Demirtas H, Ozer A, Yildirim A, Dursun A, Sezen S, Arslan M Medicina (Kaunas). 2025; 61(2).

PMID: 40005408 PMC: 11857380. DOI: 10.3390/medicina61020291.


Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.

Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204186 PMC: 11357423. DOI: 10.3390/ph17081081.


New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.

Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday I Inflammopharmacology. 2024; 32(5):3119-3161.

PMID: 38980576 DOI: 10.1007/s10787-024-01499-8.


The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.

Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675421 PMC: 11053547. DOI: 10.3390/ph17040461.


Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.

Tepes M, Krezic I, Vranes H, Smoday I, Kalogjera L, Zizek H Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004420 PMC: 10675657. DOI: 10.3390/ph16111554.


References
1.
Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D . Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008; 38(8):716-25. DOI: 10.1007/s00595-007-3706-2. View

2.
Wang X, Qu M, Duan R, Shi D, Jin L, Gao J . Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells. Neurosci Bull. 2018; 35(1):167-170. PMC: 6357276. DOI: 10.1007/s12264-018-0269-8. View

3.
Gojkovic S, Krezic I, Vranes H, Zizek H, Drmic D, Pavlov K . BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment. Biomedicines. 2021; 9(7). PMC: 8301421. DOI: 10.3390/biomedicines9070744. View

4.
Klicek R, Kolenc D, Suran J, Drmic D, Brcic L, Aralica G . Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013; 64(5):597-612. View

5.
Becejac T, Cesarec V, Drmic D, Hirsl D, Madzarac G, Djakovic Z . An endogeous defensive concept, renewed cytoprotection/adaptive cytoprotection: intra(per)-oral/intragastric strong alcohol in rat. Involvement of pentadecapeptide BPC 157 and nitric oxide system. J Physiol Pharmacol. 2018; 69(3). DOI: 10.26402/jpp.2018.3.11. View